Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is a promising medtech company with significant potential for success due to its innovative non-invasive treatment for sleep-disordered breathing. The company's transition to a new distribution strategy has resulted in short-term losses, but management is confident in the strategy's potential for greater revenue and better economics. Vivos' CARE offers a superior treatment option to the current standard of care for OSA, and its fiscal results for 2025 showed strong revenue growth and an increase in sleep testing services. However, there are risks to consider, such as potential dilution of stock and the need for additional capital. The company's recent partnerships and collaborations demonstrate its commitment to expanding its reach and offerings.

Vivos Therapeutics is a medical technology company with a high potential reward for the risks involved. However, with negative cash flows and an increasing number of outstanding shares, the company will likely require additional financing in the near term which may lead to further dilution. Additionally, the company's expenses have risen sharply as it consolidates operations, and its projection of 3.0x EV/revenue multiple is below the industry average, indicating a lower valuation. While the gross margins have shown improvement, the company's lack of steady-state gross margin and low visibility on revenues and margins are also cause for concern.